Business
Jaguar Health Announces Appointment of Martire Particco, MD, as Chief Medical Officer of Napo Therapeutics
Napo Therapeutics is focused on expanding crofelemer access in Europe for treatment of patients suffering from rare diseases - beginning with short bowel
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Napo Therapeutics is focused on expanding crofelemer access in Europe for treatment of patients suffering from rare diseases - beginning with short bowel syndrome (SBS)For SBS, Napo Therapeutics has been granted Orphan-Drug Designation for crofelemer by the European Medicines Agency, and Jaguar Health has been granted Orphan-Drug Designation for crofelemer by the FDASAN FRANCISCO, CA and MILAN, ITALY / ACCESSWIRE / January 24, 2022 / Jaguar Health (NASDAQ:JAGX) and Napo Therapeutics S.p.A., an Italian corporation established by Jaguar Health in Italy, today announced the appointment of Martire Particco, MD, a physician with 30+ years of experience in Europe's pharmaceutical industry and in clinical practice, as Chief Medical Officer of Napo Therapeutics. Dr. Particco possesses in-depth experience in the field of rare diseases, having been involved in the clinical development and launch of Pfizer's pulmonary hypertension indication for sildenafil and the clinical development of Kedrion Biopharma's ligneous conjunctivitis indication for plasminogen, with direct experience with patients and experts treating these rare pathologies.\"We are thrilled to have Dr. Particco join our team in this key leadership role in Milan,\" said Massimo Mineo, General Manager of Napo Therapeutics. \"Dr. Particco brings a wealth of experience in drug development, the management of clinical trials in and outside of Europe, and the development and execution of successful pre-launch and launch plans for drug products for rare diseases - which will support our core focus on providing access to crofelemer in Europe for our two initial and significant rare/orphan disease target indications: short bowel syndrome with intestinal failure (SBS-IF), and congenital diarrheal disorders (CDD).\"From 2016 to 2021, Dr. Particco served as Vice President, Head of Medical Affairs for Europe for Shionogi Europe, the subsidiary of a leading Japanese pharmaceutical company with global sales of €2.5 billion. Prior to this role, Dr. Particco was Shionogi Europe's Country Medical Director for Italy, and in 2013 he served as the Country Medical Director for Italy for UCB Italy, a leading European biopharmaceutical company with global sales of €4.6 billion. He also previously served as Director of Global Pharmacovigilance, Medical & Clinical Affairs at Italian firm Kedrion Bioph...